Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

Strong Phase 2 data, but key details are missing and risks remain high for investors.

What the company is saying

Avalo Therapeutics is positioning itself as a biotech innovator with a promising new therapy, abdakibart, for moderate to severe hidradenitis suppurativa (HS). The company’s core narrative is that its Phase 2 LOTUS trial delivered the highest response rates ever seen in a trial of this size or larger, specifically highlighting HiSCR75 response rates of 42.2% and 42.9% for two dosing regimens at Week 16. Management repeatedly emphasizes that the primary endpoint was met with statistical significance, and that secondary endpoints also showed statistically significant benefits, though without providing supporting numbers. The announcement is crafted to instill confidence, using phrases like “well tolerated with a favorable safety profile” and “highest absolute improvement,” while omitting granular safety data, adverse event rates, or comparative benchmarks. The tone is upbeat and assertive, projecting momentum and readiness to advance to a registrational Phase 3 program. Notable individuals such as Garry Neil, MD (CEO), and Dr. John Frew (Professor of Dermatology, University of New South Wales) are named, lending clinical and executive credibility, but no external institutional investors or partners are mentioned. The communication style fits a classic biotech playbook: highlight topline efficacy, promise future milestones, and downplay or omit operational and financial specifics. Compared to prior communications (which are not available for reference), there is no evidence of a shift in messaging, but the current announcement is tightly focused on efficacy and future plans, with little attention to commercial, financial, or operational realities.

What the data suggests

The disclosed numbers show that the LOTUS Phase 2 trial enrolled 253 adults with moderate to severe HS and ran for 16 weeks. The primary endpoint, HiSCR75 at Week 16, was achieved with response rates of 42.2% for the 150 mg dose (p=0.018) and 42.9% for the 300 mg dose (p=0.015), with a combined response rate of 42.5% versus 25.6% for placebo. These results are statistically significant and represent a meaningful improvement over placebo for the primary endpoint. However, the announcement does not provide any numerical data for secondary endpoints such as HiSCR50, IHS4, or draining tunnel count, nor does it disclose p-values or responder rates for these measures. Safety is described qualitatively as “well tolerated,” with the most common adverse events being headache and nausea, but no actual rates or severity breakdowns are given. There is also no financial data—no revenue, cash position, burn rate, or guidance—making it impossible to assess the company’s financial trajectory or runway. An independent analyst would conclude that the primary efficacy signal is real and positive, but the lack of detail on secondary endpoints and safety, as well as the absence of financial disclosure, leaves major gaps in the overall picture. The data quality is moderate for efficacy (primary endpoint only) and poor for safety and financials.

Analysis

The announcement is generally positive, with the primary endpoint of the Phase 2 trial met and clear numerical data provided for the main efficacy outcome. However, several claims regarding secondary endpoints, safety, and comparative superiority are not supported by quantitative evidence in the text. The only forward-looking claim of substance is the plan to advance to Phase 3, which is a logical next step but not yet a realised milestone. There is no disclosure of large capital outlay or immediate financial impact, and the benefits of the current results are already realised within the context of the trial. The tone is upbeat and uses superlative language, but the lack of detailed data for secondary and safety endpoints inflates the narrative somewhat relative to the evidence presented.

Risk flags

• ●Operational risk is high: The company must now design, fund, and execute a large, complex Phase 3 trial, which is a major step up in scale and complexity from Phase 2. Many drugs that succeed in Phase 2 fail in Phase 3 due to differences in patient populations, endpoints, or unforeseen safety issues.
• ●Financial risk is opaque: No financial data, cash runway, or funding plans are disclosed. Investors have no visibility into whether Avalo has the resources to complete a Phase 3 program or will need to raise dilutive capital.
• ●Disclosure risk is material: The announcement omits key numerical data for secondary endpoints and safety outcomes, making it impossible to independently verify the breadth of the efficacy or the true safety profile. This pattern of selective disclosure is a red flag for transparency.
• ●Pattern-based risk: The company uses superlative language (“highest absolute improvement,” “well tolerated”) without providing comparative benchmarks or quantitative safety data. This suggests a tendency to overstate positives and underreport negatives.
• ●Timeline/execution risk: The only forward-looking milestone is the plan to advance to Phase 3, which is years away from delivering value. Most claims are forward-looking, and the path to commercialization is long and uncertain.
• ●Geographic and regulatory risk: The trial was conducted across multiple geographies (United States, Australia, Ukraine), which can introduce variability in patient populations, regulatory standards, and operational execution.
• ●Capital intensity risk: The mention of “availability of funding sufficient for our operating expenses and capital expenditure requirements” signals that significant new capital will be needed, but no details are provided. Phase 3 trials are expensive, and the lack of a disclosed funding plan increases the risk of future dilution or financial distress.
• ●Leadership risk: While the CEO and a prominent academic are named, there is no mention of external validation, partnership, or institutional investment, which could otherwise de-risk the program or provide non-dilutive funding.

Bottom line

For investors, this announcement means Avalo Therapeutics has delivered a clear, statistically significant efficacy signal for abdakibart in a Phase 2 trial for hidradenitis suppurativa, but the story is far from complete. The topline data for the primary endpoint is credible and positive, but the lack of numerical detail for secondary endpoints and safety outcomes is a major limitation. No financial data is disclosed, so investors cannot assess the company’s cash position, burn rate, or ability to fund the next phase of development. The involvement of named executives and a respected academic lends some credibility, but there is no evidence of external institutional validation or partnership, which would be critical for de-risking a capital-intensive Phase 3 program. To change this assessment, Avalo would need to provide full numerical results for all endpoints, detailed safety data, and a transparent financial update including cash runway and funding plans. Key metrics to watch in the next reporting period include full Phase 2 data (especially secondary endpoints and safety), any partnership or licensing deals, and explicit disclosure of financial runway and capital needs. At this stage, the signal is worth monitoring but not acting on, as the risks and unknowns outweigh the single positive efficacy result. The most important takeaway: while the Phase 2 result is encouraging, the lack of transparency and looming capital and execution risks mean this is not yet a de-risked investment opportunity.

Announcement summary

Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced positive topline results from its Phase 2 LOTUS trial evaluating abdakibart in adults with moderate to severe hidradenitis suppurativa (HS). The trial met its primary endpoint of HiSCR75 at Week 16 for both the 150 mg and 300 mg doses, with response rates of 42.2% (p=0.018) and 42.9% (p=0.015), respectively, which are the highest rates observed in a trial of this size or larger. Statistically significant benefits were also demonstrated on key secondary endpoints, and abdakibart was well tolerated with a favorable safety profile. Based on these results, Avalo plans to advance abdakibart into a registrational phase 3 program. The LOTUS trial enrolled 253 adults and was conducted over a 16-week treatment period.

Disagree with this article?